IRD
Opus Genetics, Inc.
There isn't enough reported data to score IRD yet.
IRD Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
IRD's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
IRD PE Valuation
IRD has no meaningful PE right now: it lost money over the past year.
IRD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IRD's losses to grow, with revenue growing. However, they disagree widely on these estimates.
IRD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.54 | +$0.34 |
| Q2 2026 | -$1.33 | +$0.59 |
| Q1 2026 | -$1.31 | +$0.79 |
| Q4 2025 | -$0.80 | +$1.35 |
| Q3 2025 | -$1.88 | -$0.81 |
| Q2 2025 | -$1.92 | -$1.39 |
| Q1 2025 | -$2.10 | -$1.63 |
| Q4 2024 | -$2.15 | -$1.69 |
IRD is still losing money, but far less than before: $1.54 per share over the past year, against $11.55 at its worst in early 2021.
IRD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | -63% |
| Q2 2026 | $755K | -74% |
| Q1 2026 | $2.2M | -51% |
| Q4 2025 | $3.9M | -10% |
| Q3 2025 | $3.1M | -20% |
| Q2 2025 | $2.9M | +159% |
| Q1 2025 | $4.4M | +155% |
| Q4 2024 | $4.3M | +154% |
IRD's revenue has slid since its 2022 peak: $1M last quarter, down 63% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1693% | -1423 points |
| Q2 2026 | -2183% | -1874 points |
| Q1 2026 | -666% | -439 points |
| Q4 2025 | -296% | +588 points |
| Q3 2025 | -270% | -63 points |
| Q2 2025 | -309% | +440 points |
| Q1 2025 | -227% | +223 points |
| Q4 2024 | -884% | -563 points |
IRD's operating margin was −1693% last quarter, down 1423 points from the same quarter a year ago.
IRD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$12M | -$1.7M |
| Q1 2026 | -$12.7M | -$3.7M |
| Q4 2025 | -$9.8M | -$2.4M |
| Q3 2025 | -$6.2M | -$1M |
| Q2 2025 | -$10.3M | -$3M |
| Q1 2025 | -$9M | -$3.3M |
| Q4 2024 | -$7.4M | -264% |
| Q3 2024 | -$5.1M | -$2.1M |
IRD has burned cash in almost every quarter: −$41M over the past year, against −$32M the year before.
IRD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -8.6% | -9.5M shares |
| 1 year | +44% | +31.2M shares |
| 3 years | +386% | +80.9M shares |
| 5 years | +832% | +90.9M shares |
| Available history | +10187% | +101M shares |
IRD has 102M diluted shares, up 44% from a year ago.
IRD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -2.3x | Net Cash |
IRD has more cash than debt.
IRD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.5 | Neutral |
| Stochastic | 20.4 | Neutral |
IRD's weekly RSI is 50 (neutral) and its Stochastic is 20 (neutral).
IRD PE vs Healthcare Sector
| Metric | IRD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
IRD has no meaningful PE right now: it lost money over the past year.
IRD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.15 | 2.2% below |
| 20 week MA | $4.12 | 1.5% below |
| 50 week MA | $3.91 | 3.8% above |
| 100 week MA | $2.58 | 57% above |
| 200 week MA | $2.68 | 51% above |
IRD has slipped below its 8- and 20-week averages, though it's still 51% above its 200-week average.
IRD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.08 | $5.49 | -32% |
| 2021 | $5.49 | $3.81 | -31% |
| 2022 | $3.81 | $2.51 | -34% |
| 2023 | $2.51 | $3.01 | +20% |
| 2024 | $3.01 | $1.18 | -61% |
| 2025 | $1.18 | $2.02 | +71% |
| 2026 YTD | $2.02 | $4.06 | +101% |
IRD is up 101% so far in 2026, after finishing lower in four of the previous six years.